Hepatitis C News and Research

Latest Hepatitis C News and Research

Vertex presents data of telaprevir Phase 3b CONCISE study in people with genotype 1 chronic HCV

Vertex presents data of telaprevir Phase 3b CONCISE study in people with genotype 1 chronic HCV

25 Apr 2013
Democratic Sen. Harkin puts hold on Tavenner's nomination

Democratic Sen. Harkin puts hold on Tavenner's nomination

25 Apr 2013
Janssen submits Marketing Authorization Application to EMA for simeprevir approval

Janssen submits Marketing Authorization Application to EMA for simeprevir approval

25 Apr 2013
Dietary substitution of saturated fats enriched in MCT prevents liver disease

Dietary substitution of saturated fats enriched in MCT prevents liver disease

25 Apr 2013
Sofosbuvir is safer than interferon for hepatitis C patients, say scientists

Sofosbuvir is safer than interferon for hepatitis C patients, say scientists

25 Apr 2013
Targeted screening for chronic hepatitis C virus infection is cost-effective, say researchers

Targeted screening for chronic hepatitis C virus infection is cost-effective, say researchers

25 Apr 2013
Phase IIb Aviator study demonstrates high SVR rates against genotype 1 HCV

Phase IIb Aviator study demonstrates high SVR rates against genotype 1 HCV

24 Apr 2013
Data from MK-5172 Phase II study for treatment of HCV genotype 1 infection to be presented at EASL meeting

Data from MK-5172 Phase II study for treatment of HCV genotype 1 infection to be presented at EASL meeting

24 Apr 2013
Janssen announces safety results from two Phase 3 studies of simeprevir in hepatitis C patients

Janssen announces safety results from two Phase 3 studies of simeprevir in hepatitis C patients

24 Apr 2013
Home-based health education about diseases most effective, finds study

Home-based health education about diseases most effective, finds study

24 Apr 2013
New data on Enanta's lead HCV protease inhibitor to be presented at International Liver Congress

New data on Enanta's lead HCV protease inhibitor to be presented at International Liver Congress

23 Apr 2013
Clinical data on simeprevir for treatment of hepatitis C patients to be presented at EASL meeting

Clinical data on simeprevir for treatment of hepatitis C patients to be presented at EASL meeting

23 Apr 2013
Gilead Sciences to present results from four Phase 3 clinical trials at International Liver Congress 2013

Gilead Sciences to present results from four Phase 3 clinical trials at International Liver Congress 2013

23 Apr 2013
Merck, Bristol-Myers Squibb to evaluate daclatasvir and MK-5172 for treatment of HCV infection

Merck, Bristol-Myers Squibb to evaluate daclatasvir and MK-5172 for treatment of HCV infection

23 Apr 2013
DNAzymes, gold nanoparticles and disease detection: an interview with Dr Chan and Kyryl Zagorovsky, University of Toronto

DNAzymes, gold nanoparticles and disease detection: an interview with Dr Chan and Kyryl Zagorovsky, University of Toronto

23 Apr 2013
Phase 2 study of VX-661 and ivacaftor shows significant improvements in lung function among CF patients

Phase 2 study of VX-661 and ivacaftor shows significant improvements in lung function among CF patients

22 Apr 2013
Researchers decipher the underlying mechanism of antiviral drug

Researchers decipher the underlying mechanism of antiviral drug

22 Apr 2013
Indian drug supplier cuts price of 5-in-1 childhood vaccine for GAVI Alliance; Groups highlight World Immunization Week

Indian drug supplier cuts price of 5-in-1 childhood vaccine for GAVI Alliance; Groups highlight World Immunization Week

19 Apr 2013
SynCon universal H1N1 influenza vaccine generates protective antibody levels in phase 1 study

SynCon universal H1N1 influenza vaccine generates protective antibody levels in phase 1 study

19 Apr 2013
Ribavirin, interferon-alpha 2b inhibit virus replication in cell culture, NIH study finds

Ribavirin, interferon-alpha 2b inhibit virus replication in cell culture, NIH study finds

19 Apr 2013

Newsletters you may be interested in

See all Newsletters »

Terms

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

Provide Feedback